The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

**INT-0149**
The addition of chemotherapy to radiation therapy doubled the median survival time for certain patients with an aggressive form of oligodendroglioma, a rare brain tumor. Patients in the study had anaplastic oligodendrogliomas, but only those whose tumors contained a genetic abnormality known as the 1p19q co-deletion experienced a benefit from adding chemotherapy to radiation.

**ADVL0912**
Crizotinib was utilized in relapsed/refractory ALK-driven tumors, including anaplastic large cell lymphoma (ALCL) and neuroblastoma (NB), in a dose-escalation and pharmacokinetic phase 1 trial. Inhibition of ALK in pediatric patients with ALK-driven tumors occurs with minimal toxicity and is associated with high complete response rate (7/8) for ALCL. Complete responses were also observed in two patients with NB, one with documented ALK mutation.
Cooperative Group Abstracts

Breast Cancer

**ACOSOG/Alliance**


[http://meeting.americansurgical.info/abstracts/2012/3.cgi](http://meeting.americansurgical.info/abstracts/2012/3.cgi)

Protocol(s): ACOSOG-Z0010


[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94506](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94506)

Protocol(s): ACOSOG-Z1071

**CALGB/Alliance**


[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99035](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99035)

Protocol(s): CALGB-49907


[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99475](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99475)

Other Participant(s): NCCTG/Alliance

Protocol(s): CALGB-40502

**ECOG**


[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101373](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101373)

Protocol(s): E1105
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98808
Protocol(s): E5194

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97074
Protocol(s): E2Z02

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101377
Protocol(s): E5103

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94749
Protocol(s): E2197

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99178
Other Participant(s): SWOG
Protocol(s): PACCT-1

Other Participant(s): SWOG
Protocol(s): PACCT-1

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98167
Protocol(s): E2100
NCCTG/Alliance

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96940
Protocol(s): N1031

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95426
Protocol(s): N093B

NCIC Clinical Trials Group

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95125
Other Participant(s): NCCTG/Alliance
Protocol(s): NCIC-MA.27

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=93668
Other Participant(s): NCCTG/Alliance
Protocol(s): NCIC-MA.27

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95280
Protocol(s): NCIC-MA.27

NSABP

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94683
Protocol(s): NSABP-B-29
Protocol(s): NSABP-B-43

Protocol(s): NSABP-B-47

Protocol(s): NSABP-B-38

Protocol(s): NSABP-B-31

SWOG

Protocol(s): S0715
CNS Cancer

**NCCTG/Alliance**

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92558  
Protocol(s): N0877

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/5562?sid=84e7dba9-5fa1-422c-8343-ea933be7ba4c  
Protocol(s): N054C, N0776

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100091  
Protocol(s): N057K

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94341  
Protocol(s): Multiple Trials

**RTOG**

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91431  
Other Participant(s): NCCTG/Alliance, SWOG  
Protocol(s): INT-0149

http://www.ismmr.org/12/ep_05.htm  
Other Participant(s): ACRIN  
Protocol(s): RTOG-0625
Gastrointestinal Cancer

**ACOSOG/Alliance**

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92693](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92693)
Protocol(s): ACOSOG-Z4051

**CALGB/Alliance**

[http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/4514?sid=741cde25-e610-40dc-8004-f71059c2af51](http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/4514?sid=741cde25-e610-40dc-8004-f71059c2af51)
Protocol(s): C89803

Protocol(s): C89803

**ECOG**

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87848](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87848)
Protocol(s): E3200

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95820](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95820)
Protocol(s): E3205
http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=115&abstractID=88641
Protocol(s): E1201

NCCTG/Alliance

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=115&abstractID=88540
Protocol(s): N064A

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=115&abstractID=88834
Protocol(s): N0147

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=114&abstractID=96778
Protocol(s): N0147

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=114&abstractID=96648
Protocol(s): N0147

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=114&abstractID=92948
Protocol(s): N0147

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=114&abstractID=101328
Protocol(s): N0147
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98385  
Protocol(s): NSABP-P-05

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94535  
Protocol(s): NSABP-R-04

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97548  
Protocol(s): NSABP-C-08

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99494  
Protocol(s): NSABP-C-07

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99870  
Protocol(s): NSABP-C-08

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97638  
Protocol(s): NSABP-C-08

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88085  
Protocol(s): NSABP-R-04
**RTOG**


http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508512604247.pdf

**Other Participant(s): SWOG**

**Protocol(s): RTOG-97-04**

**SWOG**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100314

**Protocol(s): S0941**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92136

**Protocol(s): INT-0116**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=89317

**Protocol(s): S0000**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87914

**Protocol(s): S0205**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98448

**Protocol(s): S0727**
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87986  
Protocol(s): S0727

Genitourinary Cancer

CALGB/Alliance

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100038  
Protocol(s): CALGB-90102

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=89569  
Protocol(s): CALGB-90401

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=88999  
Protocol(s): CALGB-90401

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96038  
Protocol(s): CALGB-90401

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100283  
Protocol(s): CALGB-90401
NCIC Clinical Trials Group


Other Participant(s): ECOG, NCCTG/Alliance, SWOG
Protocol(s): T94-0110

SWOG

Protocol(s): S0000

Protocol(s): S0421

http://ajrccm.atsjournals.org/cgi/reprint/185/1_MeetingAbstracts/A6495?sid=1590afe6-88da-4223-9a2d-46bc0368b7a4
Protocol(s): S0000

Protocol(s): INT-0162

Protocol(s): S0421
Protocol(s): S0000

Protocol(s): INT-0162

Protocol(s): S0421

Protocol(s): S0353

Protocol(s): SWOG-9217

Protocol(s): S0421
**Gynecologic Cancer**

**GOG**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100631

Other Participant(s): ACRIN
Protocol(s): GOG-0262

**NCIC Clinical Trials Group**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98503

Other Participant(s): NCCTG/Alliance
Protocol(s): NCIC-160

**SWOG**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94269

Protocol(s): S0904

**Head and Neck Cancer**

**ECOG**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97623

Protocol(s): E1308


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98666

Protocol(s): E2303
Kidney Cancer

ECOG

Protocol(s): E2805

Leukemia, Myelodysplasia, and Transplantation

CALGB/Alliance

Protocol(s): CALGB-10502

Protocol(s): CALGB-100103, CALGB-10503, CALGB-19808

COG

Protocol(s): AALL07P4

Protocol(s): POG-9404

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76045

Protocol(s): ADVL0413, ADVL0613, ADVL0714, ADVL0815


http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=703&page=&back=L2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL3NhZG1pbnRzL2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL3NhZG1pbnRzLmpwZw==

Protocol(s): AALL08P1


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99179

Protocol(s): AALL0232


http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=739&page=&back=L2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL3NhZG1pbnRzL2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL3NhZG1pbnRzLmpwZw==

Protocol(s): AALL0331


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95983

Protocol(s): ALTE02C2


http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=739&page=&back=L2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL3NhZG1pbnRzL2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL3NhZG1pbnRzLmpwZw==

Protocol(s): AALL0331


http://www.connect2conferences.com/aspho4/ws_search/index.php?task=detail&abstract_id=739&page=&back=L2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL3NhZG1pbnRzL2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL2FzcGhvNG93c19zZW5kZXJhdGhvdXIucGhvZGVzL3NhZG1pbnRzLmpwZw==

Protocol(s): AALL0631
Protocol(s): A2971

Protocol(s): AALL0631

Protocol(s): P9906

**SWOG**

Protocol(s): S0703

**Lung Cancer**

**CALGB/Alliance**

Other Participant(s): NCCTG/Alliance
Protocol(s): CALGB-150601, CALGB-150802, JBR10

Protocol(s): CALGB-30704
ECOG

Hanna NH, Dahlberg SE, Kolesar J, Hirsch FR, Ramalingam SS, Schiller JH: Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). J Clin Oncol 2012; 30(Suppl): Abst. 7516.
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94015
Protocol(s): E4508

NCCTG/Alliance

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96883
Protocol(s): N0821

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92750
Protocol(s): N0321

NCIC Clinical Trials Group

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/4210?sid=b6d06d6d-11fb-47ca-ad8c-ebfbc75e8eb8
Protocol(s): JBR10

SWOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96718
Protocol(s): S0802

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98343
Protocol(s): S0722

Protocol(s): Multiple Trials


Protocol(s): S0636

West H, Moon J, Hirsch F, Mack P, Wozniak A, Lau D, Fehrenbacher L, Bury M, Redman M, Gandara D: SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). J Clin Oncol 2012; 30(Suppl): Abst. 7517. [link](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97070)

Protocol(s): S0635, S0636

Wozniak A, Moon J, Thomas CL, Kelly K, Mack PC, Gaspar LE, Raben D, Pandya KJ, Gandara DR: SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30(Suppl): Abst. 7018. [link](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92505)

Protocol(s): S0533

**Lymphoma and Plasma Cell Disorders**

**CALGB/Alliance**


Protocol(s): CALGB-50401

**COG**


Protocol(s): AHOD03P1


Protocol(s): ADVL0912
ECOG

Protocol(s): E2496

Protocol(s): E4402

SWOG

Protocol(s): S0520

Protocol(s): S0016

Protocol(s): E2496
Melanoma/Skin Cancers

ECOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95547
Protocol(s): E2607

SWOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92968
Other Participant(s): CALGB/Alliance, COG, ECOG
Protocol(s): S0008

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95522
Protocol(s): S0826

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97400
Protocol(s): S0933

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96009
Other Participant(s): CALGB/Alliance, COG, ECOG
Protocol(s): S0008
NCI’s Clinical Trials Cooperative Groups National Meetings Report

Other Cancer

**ACRIN**

[http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/53/1_MeetingAbstracts/2308](http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/53/1_MeetingAbstracts/2308)
Protocol(s): 8029, ACRIN-6684, ACRIN-6687, RTOG-0837

**CALGB/Alliance**

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91721](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91721)
Protocol(s): CALGB-170601

**COG**

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99913](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99913)
Protocol(s): ADVL0918

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100412](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100412)
Protocol(s): ADVL0813

**ECOG**

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97311](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97311)
Protocol(s): E2Z02

[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96804](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96804)
Protocol(s): E2Z02

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98987
Protocol(s): E2Z02


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=97052
Protocol(s): E2Z02


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96733
Protocol(s): E2Z02


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96850
Protocol(s): E2Z02

**NCCTG/Alliance**


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99920
Protocol(s): N00CA


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94721
Protocol(s): N07C2


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101392
Protocol(s): N0392
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100961
Protocol(s): N04C7, N05C3

SWOG

Protocol(s): S0000

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99141
Protocol(s): S0711

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100857
Protocol(s): Multiple Trials

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1ca1b018-6374-4e10-b351-ed4e89a1111b&cKey=61a3697d-d4d7-4813-9a65-c08fd72bd8f&mKey={2D8C569E-B72C-4E7D-AB3B-070BEC7EB280

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95239
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96679

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94823

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100819

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100924

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1ca1b018-6374-4e10-b351-ed4e89a1111b&cKey=302d20f8-8015-402e-8297-965ab6112618&mKey={2D8C569E-B72C-4E7D-AB3B-070BEC7EB280}

Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References only appear under one disease heading and the Lead Cooperative Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the required information is available. Links to online abstracts are provided if they were available at the time of publication, but there is no guarantee that these links will remain active.